Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 760-767

  Aghazadeh Habashi, Ali ^a   Gilzad Kohan, M H ^a   Asghar, Waheed ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adjuvant arthritis; Dose effect correlation; Drug effects; Minimum effective dose; Pharmacokinetics; Rat

Indexed keywords

GLUCOSAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRITE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; MAXIMUM PLASMA CONCENTRATION; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; WEIGHT GAIN;

ADJUVANT ARTHRITIS; DOSE-EFFECT CORRELATION; DRUG EFFECTS; MINIMUM EFFECTIVE DOSE; PHARMACOKINETICS; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; ARTHRITIS, EXPERIMENTAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSAMINE; INTERLEUKIN-1BETA; INTERLEUKIN-6; JOINTS; MALE; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 84895918804     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23819     Document Type: Article

References (40)

1. Harirforoosh S, Asghar W, Jamali F, 2013. Adverse effects of nonsteroidal anti-inflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. In press.
2. Beasley J. 2012. Osteoarthritis and rheumatoid arthritis: Conservative therapeutic management. J Hand Ther 25:163-172.
3. Davies NM, Jamali F. 2004. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. J Pharm Pharm Sci 7:332-336.
4. Hua J, Suguro S, Hirano S, Sakamoto K, Nagaoka I. 2005. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflam Res 54:127-132.
5. Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. 2007. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 27:213-218.
6. Matsuno H, Nakamura H, Katayama K, Hayashi S, Kano S, Yudoh K, Kiso Y. 2009. Effects of an oral administration of glucosaminechondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis. Biosci Biotech Biochem 73:288-292.
7. Alptekin DO. 2009. The efficacy of glucosamine and chondroitin sulfate in osteoarthritis management: Review. Turk Klinikleri J Med Sci 29:1687-1694.
8. Roman Blas JA, Castaneda S, Largo R, Herrero Beaumont G. 2010. Glucosamine sulfate for knee osteoarthritis: Science and evidencebased use. Therapy 7:591-604.
9. Aghazadeh-Habashi A, Jamali F. 2011. The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci 14:264-273.
10. Russell AS, Aghazadeh-Habashi A, Jamali F. 2002. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 29:2407-2409.
11. Anderson JW, Nicolosi RJ, Borzelleca JF. 2005. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 43:187-201.
12. Byrne J. 2010. Glucosamine market reaching maturity. Accessed April 15, 2010, at: http://www.nutraingredientsusa.com/Industry/Glucosamine-market- reachingmaturity.
13. Zhang LJ, Huang TM, Fang XL, Li XN, Wang QS, Zhang ZW, Sha XY. 2006. Determination of glucosamine sulfate in human plasma by precolumn derivatization using high performance liquid chromatography with fluorescence detection: Its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 842:8-12.
14. Jackson CG, Plaas AH, Sandy JD, Hua C, Kim-Rolands S, Barnhill JG, Harris CL, Clegg DO. 2010. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 18:297-302.
15. Arti HR, Azemi ME. 2012. Comparing the effect of glucosamine and glucosamine with alendronate in symptomatic relieve of degenerative knee joint disease: A double-blind randomized clinical trial study. Jundishapur J Nat Pharm Prod 7:87-92.
16. Durmus D, Alayli G, Bayrak IK, Canturk F. 2012. Assessment of the effect of glucosamine sulfate and exercise on knee cartilage using magnetic resonance imaging in patients with knee osteoarthritis: A randomized controlled clinical trial. J Back Musculoskel Rehab 25:275-284.
17. Wilkens P, Storheim K, Scheel I, Berg L, Espeland A. 2012. No effect of 6-month intake of glucosamine sulfate on Modic changes or high intensity zones in the lumbar spine: Sub-group analysis of a randomized controlled trial. J Neg Res Bio Med 11:1-10.
18. Reginster JY, Neuprez A, Lecart MP, Sarlet N, Bruyere O. 2012. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int 32:2959-2967.
19. Kwon HB, Ahn BJ, Choi Y, Jin SY, Cheong KA, Lee J, Lee AY. 2013. Combination of glucosamine improved therapeutic effect of lowdose cyclosporin A in patients with atopic dermatitis: A pilot study. J Dermatol 40:207-210.
20. Bendele A, Mccomb J, Gould T, Mcabee T, Sennello G, Chlipala E, Guy M. 1999. Animal models of arthritis: Relevance to human disease. Toxicol Pathol 27:134-142.
21. Hussein MR, Fathi NA, El-Din AME, Hassan HI, Abdullah F, Al-Hakeem E, Backer EA. 2008. Alterations of the CD4 +, CD8 + T cell subsets, interleukins-1$, IL-10, IL-17, tumor necrosis factor-" and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: Preliminary observations. Pathol Oncol Res 14:321-328.
22. Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. 1997. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis? Arthritis Rheum 40:5-18.
23. Piquette-Miller M, Jamali F. 1995. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Disposition 23:240-245.
24. Grisham MB, Johnson GG, Lancaster JR Jr. 1996. Quantitation of nitrate and nitrite in extracellular fluids. Meth Enzymol 268:237-246.
25. Gilzad-Kohan MH, Jamali F. 2012. Glucosamine and adjuvant arthritis: A pharmacokinetic and pharmacodynamic study. Eur J Pharm Sci 47:387-393.
26. Ibrahim A, Gilzad-kohan MH, Aghazadeh-Habashi A, Jamali F. 2012. Absorption and bioavailability of glucosamine in the rat. J Pharm Sci 101:2574-2583.
27. Ibrahim A, Jamali F. 2010. Improved sensitive high performance liquid chromatography assay for glucosamine in human and rat biological samples with fluorescence detection. J Pharm Pharm Sci 13:128-135.
28. Jamali F, Brocks DR. 1990. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharm 19:197-217.
29. Mayo PR, Skeith K, Russell AS, Jamali F. 2000. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-613.
30. Oegema TRJ, Deloria LB, Sandy JD, Hart DA. 2002. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapaininjected knees of young rabbits. Arthritis Rheum 46:2495-2503.
31. Wen ZH, Tang CC, Chang YC, Huang SY, Hsieh SP, Lee CH, Huang GS, Ng HF, Neoh CA, Hsieh CS, Chen WF, Jean YH. 2010. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: Association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthritis Cartilage 18:1192-1202.
32. Towheed TE, Anastassiades T. 2007. Glucosamine therapy for osteoarthritis: An update. J Rheumatol 34:1787-1790.
33. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P. 2012. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465-474.
34. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Bingham CO, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. 2010. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 69:1459-1464.
35. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. 2006. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 65:222-226.
36. Block JA, Oegema TR, Sandy JD, Plaas A. 2010. The effects of oral glucosamine on joint health: Is a change in research approach needed? Osteoarthritis Cartilage 18:5-11.
37. Conforti A, Lussignoli S, Bertani S, Ortolani R, Cuzzolin L, Benoni G, Bellavite P. 2001. Cytokine and nitric oxide levels in a rat model of immunologic protection from adjuvant-induced arthritis. Int J Immunopathol Pharmacol 14:153-160.
38. Nagy G, Koncz A, Telarico T, Fernandez D, Ersek B, Buzas E, Perl A. 2010. Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 12:210.
39. Lindner MD, Plone MA, Francis JM, Cain CK. 1999. Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Exp Clin Psychopharmacol 7:187-197.
40. Kulmatycki KM, Jamali F. 2005. Drug disease interactions: Role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci 8:602-625.